Pediculosis is an infestation of lice from the sub-order Anoplura, family Pediculidae. Accordingly, the infestation with head lice is named pediculosis capitis, while this with body lice, pediculosis corporis. Although pediculosis in humans may properly refer to lice infestation of any part of the body, the term is sometimes used loosely to refer to pediculosis capitis, the infestation of the human head with the specific head louse. Classification
Pediculosis may be divided into the following types:: 446–8 
Pediculosis capitis (Head lice infestation)
Pediculosis corporis (Body louse infestation, also known as Pediculosis vestimenti, Vagabonds disease)
Pediculosis pubis (Pubic louse infestation, also known as phthiriasis)

Head lice
Presentation
Head-lice infestation is most frequent on children aged 3–10 and their families. Approximately 3% of school children in the United States contract head lice. Females aged 3–12 years are most commonly infested. Those of African descent rarely experience infestation due to differences in hair texture.Head lice are spread through direct head-to-head contact with an infested person. From each egg or "nit" may hatch one nymph that will grow and develop to the adult louse. Lice feed on blood once or more often each day by piercing the skin with their tiny needle-like mouthparts. While feeding they excrete saliva, which irritates the skin and causes itching. Lice cannot burrow into the skin. Diagnosis
To diagnose infestation, the entire scalp should be combed thoroughly with a louse comb and the teeth of the comb should be examined for the presence of living lice after each time the comb passes through the hair.
1-Deoxygalactonojirimycin (DGJ) has been shown to be both a potent competitive inhibitor of α-GAL and an effective chaperone to for Fabry disease, increasing intracellular α-GALs activity by 14-fold. Modifying blood type group B to group O
α-GAL, known as B-zyme in this context, has also demonstrated its ability to convert human blood group B to human blood group O, which can be transfused to patients of all blood types in the ABO blood group categorization. The current B-zyme used comes from Bacteroides fragilis. The idea of maintaining a blood supply at healthcare facilities with all non-O units converted to O units is achieved using enzyme-converted to group O technology, first developed in 1982. Advantages
A blood bank with ECO blood demonstrates the following advantages:
Compatible with and transfusable to patients of all blood groups
Reduce the demand for specific ABO blood groups A, B, AB
Reduce cost of maintaining a blood bank inventory in hospitals
Reduce blood transfusion reactions due to human error and ABO incompatibility
Reduce wastage of less needed blood types

Mechanism of Action
Red blood cell (RBC) surfaces are decorated with the glycoproteins and glycolipids that have the same basic sequence with terminal sugar α1‐2‐linked fucose linked to the penultimate galactose. This galactose molecule is called the H antigen. Blood type A, B, AB, and O differ only in the sugar (red molecule in the illustration) linked with the penultimate galactose. For blood type B, this linked sugar is an α-1‐3‐linked galactose. Using α-GAL, this terminal galactose molecule can be removed, converting RBC to type O.